GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
LA JOLLA, CA, April 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the fiscal year ended December 31, 2023 and provided a corporate update.
- IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream.
- GRI Bio’s lead program, GRI-0621, is a small molecule RAR-βɣ dual agonist that inhibits the activity of human iNKT cells.
- Research and development expenses were $3.2 million and $0.2 million for the years ended December 31, 2023 and 2022, respectively.
- General and administrative expenses were $8.2 million and $2.0 million for the years ended December 31, 2023 and 2022, respectively.